Checkpoint Inhibitors in Cancer Care

Waystar's AI-powered AltitudeAI automates claim appeals, aiming to recover billions in denied payments and reduce healthcare administrative waste.

In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.

In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible newly diagnosed multiple myeloma.

Matthew Hadfield, DO, discusses his passion for early-stage clinical trials and the need for more research into immunotherapy toxicities during the third episode of Emerging Experts.

Peers & Perspectives in Oncology editorial board member Marc J. Braunstein, MD, PhD, FACP, discussed the significant advancements in multiple myeloma treatment at the 2024 ASH Annual Meeting and Exposition.

During a Case-Based Roundtable® event, Jay Yang, MD, discussed the trial comparing luspatercept with ESA in myelodysplastic syndrome.